New drug controls body's signals for eating

A research team at Hebrew University on Jerusalem has developed a drug that mimics the activity of the hormone aMSH, which spurs the feeling of fullness. The hormone binds to a receptor in the brain that sends out the signal to the body that it is full. The researchers, led by a grad student, developed a synthetic peptide called BL-3020 that was able to enter the bloodstream, make its way to the receptor and emit the 'full' signal. Testing the therapy on mice over 24 hours, researchers noted a reduction in eating. Over a 12-day period, the mice dropped to a weight that was 40 percent below normal. Israel's Bioline RX bought the development rights.

- read the report from Scenta

ALSO: A new study indicates that mutations in the gene known as brain specific homeobox transcription factor might explain why some people fidget less and put on more weight. German engineers developed a mouse model without the Bsx factor and found they had accumulated more weight than normal mice over a period of three months. Report

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.